Feb 22, 2022 | Press Releases
Advancement of additional studies is based on positive results from in vitro studies and the ongoing COVID-19 pandemicMARLBOROUGH, Mass., Feb. 22, 2022 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical-stage biotechnology company developing the next...
Jan 11, 2022 | Press Releases
French regulatory authorities grant Clinical Trial Authorization with dosing of first patient anticipated in the first quarter of 2022 MARLBOROUGH, Mass., Jan. 11, 2022 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next...
Jan 3, 2022 | Press Releases
MARLBOROUGH, Mass., Jan. 3, 2022 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today...
Nov 12, 2021 | Press Releases
MARLBOROUGH, Mass., Nov. 12, 2021 — Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today...
Nov 10, 2021 | Press Releases
Lead program, PH-762, is on track to enter first-in-human clinical study in Q1 2022Presented data at the ESMO Congress 2021 showing Dual-Targeting INTASYL PH-3861 induced a durable and specific systemic anti-tumor immune response following local...
Oct 18, 2021 | Press Releases
MARLBOROUGH, Mass., Oct. 18, 2021 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today...
